08:12 AM EDT, 06/18/2025 (MT Newswires) -- Biomea Fusion ( BMEA ) said Wednesday that preclinical data for its investigational weight loss drug, BMF-650, showed "robust weight loss and appetite suppression."

The study, conducted with monkeys, showed 12% to 15% body weight reductions over 28 days, the company said.

BMF-650 was well-tolerated, the company said, adding that plans to file an investigational new drug application in H2 are on track.

Following clearance of the application, a phase 1 trial in obese but otherwise healthy volunteers is expected to begin in late 2025, the company said.